{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["Sanz-Munoz I"],"pubmed_abstract":["<h4>Introduction</h4>The third dose of the COVID-19 vaccine is especially necessary in people over 65 years of age due to their lower immune response.<h4>Methods</h4>We designed a multicentre, prospective observational study including 98 people ≤65 years old who lived in two nursing homes in Valladolid, Spain. One of the groups had previous experience with SARS-CoV-2 (n=68;69.4%) and the other was naïve (n=30;30.6%). We evaluated the response to the three doses of the Comirnaty vaccine and the dynamics of antibodies during 5 consecutive serum samplings: 2 after the first two doses of vaccination, one three months after the first dose, another at 6 months and the last one month after the third dose. IgG antibodies against SARS-CoV-2 S1, RBD and N antigens were analysed.<h4>Results</h4>Both "],"journal":["Frontiers in immunology"],"pagination":["1128302"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9992205"],"repository":["biostudies-literature"],"pubmed_title":["Evolution of antibody profiles against SARS-CoV-2 in experienced and naive vaccinated elderly people."],"pmcid":["PMC9992205"],"pubmed_authors":["de Lejarazu-Leonardo RO","Castrodeza-Sanz J","Sanchez-de Prada L","Rojo-Rello S","Hernan-Garcia C","Gonzalez MD","Lopez-Mongil R","Eiros JM","Fernandez-Espinilla V","Sanchez-Martinez J","Sanz-Munoz I","Perez-SanJose D"],"additional_accession":[]},"is_claimable":false,"name":"Evolution of antibody profiles against SARS-CoV-2 in experienced and naive vaccinated elderly people.","description":"<h4>Introduction</h4>The third dose of the COVID-19 vaccine is especially necessary in people over 65 years of age due to their lower immune response.<h4>Methods</h4>We designed a multicentre, prospective observational study including 98 people ≤65 years old who lived in two nursing homes in Valladolid, Spain. One of the groups had previous experience with SARS-CoV-2 (n=68;69.4%) and the other was naïve (n=30;30.6%). We evaluated the response to the three doses of the Comirnaty vaccine and the dynamics of antibodies during 5 consecutive serum samplings: 2 after the first two doses of vaccination, one three months after the first dose, another at 6 months and the last one month after the third dose. IgG antibodies against SARS-CoV-2 S1, RBD and N antigens were analysed.<h4>Results</h4>Both ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-04-04T18:50:48.858Z","creation":"2025-04-04T18:50:48.858Z"},"accession":"S-EPMC9992205","cross_references":{"pubmed":["36911673"],"doi":["10.3389/fimmu.2023.1128302"]}}